All In Biotech

Drug Trial Radar · NCT06542497

Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia

Randomized, Double-masked, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Phentolamine Ophthalmic Solution (POS) 0.75% in Participants With Presbyopia

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 569 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

569

Actual

Start

Aug 15, 2024

Primary completion

Apr 3, 2025

Study completion Jan 22, 2026

Sponsor

Lead sponsor
Opus Genetics, IncIndustry
Sponsor type
Industry
First posted
Aug 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Safety and efficacy of POS in participants with presbyopia

Conditions

  • Presbyopia

Interventions

  • 0.75% phentolamine ophthalmic solutionDrug

    Once daily dosing

  • PlaceboDrug

    Once daily dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With ≥ 15 Letters of Improvement in Binocular DCNVA and With < 5 Letters of Loss in Binocular BCDVA From Baseline Comparing POS-treated Participants to Placebo-treated Participants at 12 Hours Post-dose at Visit 4 (Day 8)Time frame: 8 Days

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Eye Center

    Chandler, Arizona

  • Carrot Eye Center

    Mesa, Arizona

  • Eye Doctors of Arizona

    Phoenix, Arizona

  • MRB Eye Care Consultants, LLC

    Scottsdale, Arizona

  • Empire Eye & Laser Center

    Bakersfield, California

  • Global Research Management, Inc.

    Glendale, California

  • Gordon Schanzlin New Vision Institute

    La Jolla, California

  • LoBue Laser and Eye Medical Center, Inc.

    Murrieta, California

  • Eye Research Foundation

    Newport Beach, California

  • Wolstan and Goldberg Eye Associates

    Torrance, California

  • Segal Drug Trials, Inc.

    Delray Beach, Florida

  • South Florida Glaucoma

    Delray Beach, Florida

  • Levenson Eye

    Jacksonville, Florida

  • Bowden Eye & Associates

    Jacksonville, Florida

  • Shettle Eye Research

    Largo, Florida

  • Sabal Eye Care/dba Omega Vision Center

    Longwood, Florida

  • Mid Florida Eye Center

    Mt. Dora, Florida

  • Virdi Eye Clinic

    Rock Island, Illinois

  • Price Vision Group

    Indianapolis, Indiana

  • Durrie Vision

    Overland Park, Kansas

  • Kannarr Eye Care

    Pittsburg, Kansas

  • Heart of America Eye Care, P.A.

    Shawnee Mission, Kansas

  • The Eye Care Institute

    Louisville, Kentucky

  • Fraser Eye Care Center

    Fraser, Michigan

  • Moyes Eye Center

    Kansas City, Missouri

  • Rochester Ophthalmological Group

    Rochester, New York

  • Oculus Research , Inc.

    Garner, North Carolina

  • Bergstrom Eye

    Fargo, North Dakota

  • Red River Research Partners

    Fargo, North Dakota

  • Athens Eye Care

    Athens, Ohio

  • West Bay Eye Associates

    Warwick, Rhode Island

  • Advancing Vision Research

    Goodlettsville, Tennessee

  • Optometry Group

    Memphis, Tennessee

  • Total Eye Care

    Memphis, Tennessee

  • Whitsett Vision Group

    Houston, Texas

  • Lake Travis Eye and Laser Center/ Revolution Research

    Lakeway, Texas

  • Red River Research Partners

    Richardson, Texas

  • Parkhurst NuVision

    San Antonio, Texas

  • Eye Institute of Utah

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.